Canada warns against sex enhancement drug
This article was originally published in The Tan Sheet
Executive Summary
Canadian consumers are warned against using Adam, an unauthorized product for erectile dysfunction, as it may pose serious health risks, especially for patients with pre-existing medical conditions, Health Canada says in a statement March 10. The product contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil, which is used under the supervision of a physician, the agency says. Heart disease patients who use sildenafil can experience cardiovascular side effects including heart attack and stroke, Health Canada notes. Distributor Natural Health Solutions conducted a voluntary recall of Adam, which was sold in retail outlets throughout Canada and on the Internet. Due to the proliferation of erectile dysfunction supplements containing prescription ingredients in the U.S., the United Natural Products Alliance is urging the supplement industry to take steps to keep these products off the market (1"The Tan Sheet" Jan. 28, 2008, p. 11)...
You may also be interested in...
FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA
The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.